September 28, 2019
Seattle Genetics, Astellas Phase 1 Trial of Investigational Agent Enfortumab Vedotin plus Pembrolizumab met outcomes: 71% patients confirm response.
Seattle Genetics, and Astellas Pharma’s study met outcomes for safety and 71 Percent of patients with locally advanced or metastatic urothelial (bladder) cancer had a confirmed response, the companies presented Saturday at ESMO Congress in Barcelona.